Loading institutional data...
Loading institutional data...
Held by 282 of 5,944 reporting institutions (94th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $118.06 today, the market must believe free cash flow compounds 8.5%/yr for a decade (off $106M normalized FCF).
The market's 8.5% is more conservative than its 8-yr track record.
2-stage DCF · 0.02B shares · net debt $39M
mean 161.2% · volatility σ 462% · implied rate exceeded in 2/8 yrs
Central path = implied 8.5%/yr growth; shaded band = ±1σ (462%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| ADUS | $2.2B | 22.6× | 14.4× | 1.6× | 23.2% | 32.5% | 6.7% | 8.8% | 8.0% | 0.8× | 282 |
Peers = companies sharing ADUS's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $104M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: 8%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~11.3% on $121M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 14-yr range · 39th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 1.5× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 73.5 | 72.4 | 70.4 | 68.8 | 68.5 | 67.9 | 67.5 | 67.5 |
| Gross Profit | 26.5 | 27.6 | 29.6 | 31.2 | 31.5 | 32.1 | 32.5 | 32.5 |
| SG&A | 20.4 | 20.6 | 22.2 | 21.9 | 22.8 | 22.2 | 22.4 | 21.6 |
| Operating Income | 4.4 | 5.4 | 5.8 | 7.6 | 7.2 | 8.6 | 8.9 | 9.7 |
| Income Tax | 0.8 | 1.1 | 1.2 | 1.8 | 1.5 | 1.8 | 2.2 | 2.2 |
| Net Income | 3.2 | 3.9 | 4.3 | 5.2 | 4.8 | 5.9 | 6.4 | 6.7 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ADUS: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.42B 100.0% | $1.15B 100.0% | $1.06B 100.0% | $951.1M 100.0% | $864.5M 100.0% | $764.8M 100.0% | $648.8M 100.0% | $516.6M 100.0% | $426.0M 100.0% | $400.9M 100.0% |
| Cost of Revenue | $960.7M 67.5% | $779.6M 67.5% | $718.8M 67.9% | $651.4M 68.5% | $594.7M 68.8% | $538.5M 70.4% | $469.6M 72.4% | $379.8M 73.5% | $310.1M 72.8% | $294.6M 73.5% |
| Cost of Services | — | — | — | — | — | — | — | — | $310.1M 72.8% | $294.6M 73.5% |
| Gross Profit | $461.9M 32.5% | $375.0M 32.5% | $339.9M 32.1% | $299.7M 31.5% | $269.8M 31.2% | $226.2M 29.6% | $179.2M 27.6% | $136.8M 26.5% | $115.9M 27.2% | $106.3M 26.5% |
| Selling, General & Admin | $306.8M 21.6% | $258.8M 22.4% | $234.8M 22.2% | $216.9M 22.8% | $189.4M 21.9% | $169.7M 22.2% | $133.9M 20.6% | $105.3M 20.4% | $76.9M 18.1% | $76.8M 19.2% |
| Total Operating Expenses | $323.3M 22.7% | $272.3M 23.6% | $248.9M 23.5% | $231.0M 24.3% | $203.9M 23.6% | $181.7M 23.8% | $144.5M 22.3% | $114.0M 22.1% | $90.6M 21.3% | $90.9M 22.7% |
| Operating Income | $138.6M 9.7% | $102.7M 8.9% | $91.0M 8.6% | $68.7M 7.2% | $65.9M 7.6% | $44.5M 5.8% | $34.8M 5.4% | $22.8M 4.4% | $25.3M 5.9% | $15.5M 3.9% |
| Interest Expense | $13.6M 1.0% | $7.7M 0.7% | $11.1M 1.0% | $8.9M 0.9% | $5.8M 0.7% | $3.2M 0.4% | $3.1M 0.5% | $5.0M 1.0% | $4.5M 1.0% | $2.3M 0.6% |
| Interest & Investment Income | $2.4M 0.2% | $4.4M 0.4% | $1.5M 0.1% | $341K 0.0% | $268K 0.0% | $624K 0.1% | $1.5M 0.2% | $2.6M 0.5% | $66K 0.0% | $2.8M 0.7% |
| Pretax Income | $127.4M 9.0% | $99.4M 8.6% | $81.3M 7.7% | $60.2M 6.3% | $60.4M 7.0% | $41.9M 5.5% | $33.2M 5.1% | $20.4M 3.9% | $21.1M 4.9% | $16.2M 4.0% |
| Income Tax Expense | $31.5M 2.2% | $25.8M 2.2% | $18.8M 1.8% | $14.1M 1.5% | $15.3M 1.8% | $8.8M 1.2% | $7.4M 1.1% | $4.1M 0.8% | $9.3M 2.2% | $4.1M 1.0% |
| Net Income | $95.9M 6.7% | $73.6M 6.4% | $62.5M 5.9% | $46.0M 4.8% | $45.1M 5.2% | $33.1M 4.3% | $25.2M 3.9% | $16.4M 3.2% | $12.0M 2.8% | $12.2M 3.0% |
| Per Share | ||||||||||
| EPS (Basic) | $5.31 | $4.33 | $3.91 | $2.90 | $2.87 | $2.12 | $1.83 | $1.36 | $1.04 | $1.07 |
| EPS (Diluted) | $5.22 | $4.23 | $3.83 | $2.84 | $2.81 | $2.08 | $1.77 | $1.33 | $1.03 | $1.07 |
| Weighted Avg Shares (Basic) | 18.1M | 17.0M | 16.0M | 15.9M | 15.7M | 15.6M | 13.8M | 12.0M | 11.5M | 11.3M |
| Weighted Avg Shares (Diluted) | 18.4M | 17.4M | 16.3M | 16.2M | 16.1M | 16.0M | 14.2M | 12.4M | 11.6M | 11.3M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position